Macimorelin Protocol — Complete Dosing & Administration Guide

Dosing

How muchdo I take?

Oral: Taken by mouth as a capsule, tablet, or liquid.

Bioavailability Varies by compound — many peptides are largely broken down in the gut, so little reaches the blood intact; some small molecules absorb well.

Standard Dose

0.5 mg/kg

Frequency

Single dose

Duration

One-time diagnostic test

FDA-label (Macrilen) single oral dose for diagnosing adult growth hormone deficiency. Granules (60 mg) are reconstituted in 120 mL water (0.5 mg/mL) and taken after an 8-hour fast; serum GH below 2.8 ng/mL across the 30/45/60/90-minute draws confirms deficiency [4].

Timing

Best time to take

Early morning, after fasting overnight for at least 4 hours

With food?

Must be taken on an empty stomach. Food decreases absorption by 50-55%. Do not eat for at least 1 hour before and 30 minutes after administration.

If stacking

This is a single-use diagnostic test, not a compound to be stacked. Administered once with baseline and stimulated GH measurements at 30, 45, and 60 minutes post-dose.

Adjusting Your Dose

Increase if

+Initial test is inconclusive and retesting is clinically indicated

+Patient weight changes significantly between test administrations

+Clinical suspicion remains high despite initial negative result

Decrease if

-Not applicable — single fixed dose based on weight

-Dose is calculated once at 0.5 mg/kg body weight

Signs of right dose

✓Clear GH response meeting diagnostic criteria at 2-minute interval

✓GH level above 2.8 ng/mL threshold (positive test)

✓Minimal side effects or patient tolerability issues

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

The weight is on the label

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do Iuse it?

Reconstitution

What you need

•Macrilen powder vial (25 mg or 50 mg)

•Sterile water for injection (pharmaceutical grade)

•Small glass of water (8 oz) for dilution

•Graduated cylinder or syringe for measuring

•Small spoon or stirring device

Example

For a 70 kg patient: 70 kg × 0.5 mg/kg = 35 mg total dose. If using a 25 mg vial, reconstitute with appropriate volume of water to achieve desired concentration.

Dose (mg) = Patient body weight (kg) × 0.5 mg/kg. Round dose to nearest mg if needed. Single oral dose dissolved in water, taken on empty stomach.

Injection

Route

Not applicable — oral solution only

Best sites

•Not applicable (oral administration)

Technique

1.Reconstitute powder with sterile water according to package instructions

2.Stir gently until completely dissolved

3.Solution should be clear and colorless

4.Drink entire solution immediately or within specified timeframe

5.Do not inject or inhale

Storage

Before reconstitution

Store in refrigerator at 2-8°C (36-46°F). Protect from light. Keep in original container until time of use.

After reconstitution

Once reconstituted in water, solution must be used within 30 minutes. Do not refrigerate after reconstitution. Discard any unused portion.

Signs of degradation

Solution becomes cloudy or discolored

Precipitate or particles visible in solution

Odor changes from odorless to unpleasant

Solution separated or layered appearance

More than 30 minutes have passed since reconstitution

Sample Daily Schedule

Early morning (8-9 AM typical)

0.5 mg/kg body weight (25-60 mg based on weight) injection

Site: Oral administration

Patient must fast overnight (minimum 4 hours). After dosing, measure blood GH at baseline, 30, 45, and 60 minutes. Positive test = GH > 2.8 ng/mL.

Safety

Is itsafe?

Safety Profile

Macimorelin is well-tolerated with an excellent safety profile in clinical trials. No serious adverse events were reported in Phase 3 studies (n=154). Most side effects are mild and transient. QT prolongation of approximately 11 msec occurs but is generally not clinically significant. However, avoid combining with other QT-prolonging drugs.

Safety data from Phase 3 clinical trial (NCT02558829, 157 subjects) and FDA approval process demonstrating efficacy and safety equivalent to insulin tolerance test with superior convenience and tolerability.

Common Side Effects

Experienced by some users

Dysgeusia (abnormal taste)

Metallic or unpleasant taste in mouth affecting 4.5% of patients. Often described as a bitter or medicinal aftertaste. Occurs within minutes of taking the dose and typically resolves within 1-2 hours.

Management: Eat something sweet or drink a flavored beverage after the required fasting window. Swish mouth with water. Taste usually resolves spontaneously. Does not interfere with test results.

Dizziness

Mild dizziness or lightheadedness in 3.9% of patients. Usually mild and transient, resolving within 1-2 hours. May be related to fasting state and GH stimulation.

Management: Sit or lie down if dizziness occurs. Stay well-hydrated. Avoid sudden position changes. Dizziness resolves as GH levels normalize. No intervention usually needed.

Headache

Mild to moderate headache in 3.9% of patients. Typically mild and non-throbbing. Occurs within first few hours after dosing. Similar incidence to placebo in some analyses.

Management: Rest in a quiet, dark environment. Over-the-counter pain relief (acetaminophen or ibuprofen) is safe if needed. Drink plenty of water. Usually resolves within 2-4 hours without intervention.

Fatigue

Mild fatigue or tiredness in 3.9% of patients. May be related to morning testing and fasting state. Typically mild and short-lived.

Management: Schedule test when able to rest afterward. Avoid strenuous activity immediately after testing. Fatigue usually resolves within 2-4 hours. Eat a light meal after the testing window concludes.

Nausea

Mild nausea in 3.2% of patients. Rarely progresses to vomiting (less than 1% of cases). Related to fasting state and GH stimulation. Transient and mild when it occurs.

Management: Remain still and breathe deeply. Avoid sudden movements. Eat bland foods after testing window. Ginger tea or peppermint may help. Does not typically interfere with diagnostic test.

Increased Appetite

Hunger or increased appetite stimulation in 3.2% of patients. Expected physiologic response since macimorelin stimulates ghrelin/hunger pathways. Occurs during test window.

Management: This is expected during the diagnostic test. Eat a meal immediately after the 60-minute testing window concludes. Hunger resolves once food is consumed. Does not affect test validity.

Stop and Seek Help If

×Test has been completed and diagnostic results obtained (single-use diagnostic tool)

×Patient develops signs of QT prolongation or cardiac arrhythmias

×Patient experiences severe hypersensitivity reaction

×Contraindications emerge that preclude continued testing

×Physician determines additional testing is not clinically warranted

Macimorelin is a single-dose diagnostic test, not an ongoing therapy. Once administered and blood samples collected, the diagnostic protocol is complete. Additional testing requires a separate administration if clinically indicated by the healthcare provider.

Interactions

With other peptides

!Should not be combined during diagnostic testing as it will confound results

!Discontinue GH therapy 4+ weeks before testing if possible to avoid false negatives

With medications

!QT-prolonging drugs (quinidine, disopyramide, amiodarone, sotalol, dofetilide, antipsychotics, antiemetics) - Increases risk of QT prolongation and torsades de pointes. Avoid combination or use extreme caution with ECG monitoring.

!CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) - May increase macimorelin exposure and side effects. Monitor for increased QT prolongation.

!Medications affecting electrolytes (diuretics, amphotericin B) - Electrolyte abnormalities increase QT prolongation risk. Ensure normal K+ and Mg+ before testing.

!Corticosteroids or opioids - May blunt GH response to macimorelin. Discontinue if possible before testing.

With supplements

✓Supplements affecting heart rhythm (stimulants with high caffeine) - Extreme caffeine intake before testing may increase arrhythmia risk. Recommend abstinence 24 hours before test.

Want the Full Picture?

View the complete Macimorelin research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.